Skip to main content

Table 1 Baseline characteristics according to patient clusters

From: Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

N = 9363 Cluster 1
Non-CV comorbidities
N = 3634
Cluster 2
Low risk
N = 2774
Cluster 3
CV RFs/comorbidities
N = 2955
P
Age, years Median [IQR] 73 [65–78] 65 [56–72] 73 [66–78] < .001
Age classes, n (%)     < .001
< 65 years 865 (23.8) 1351 (48.7) 659 (22.3)  
65–74 years 1216 (33.5) 910 (32.8) 1039 (35.2)  
75–84 years 1282 (35.3) 441 (15.9) 1068 (36.1)  
≥ 85 years 271 (7.5) 72 (2.6) 189 (6.4)  
Females, n (%) 1604 (44.1) 964 (34.8) 1138 (38.5) < .001
Overweight/obese, n (%) 755 (20.8) 1666 (60.1) 1619 (54.8) < .001
Smoking habit, n (%) 1218 (33.5) 996 (35.9) 947 (32.0) 0.008
Alcohol habit, n (%) 1088 (33.7) 1004 (41.0) 786 (29.8) < 0.001
Reason for admission, n (%)     < .001
AF 2427 (66.8) 2299 (82.9) 1571 (53.2)  
Other CV 1034 (28.5) 400 (14.4) 1221 (41.3)  
Other non-CV 173 (4.8) 75 (2.7) 163 (5.5)  
Site of admission, n (%)     < .001
Hospital facility 1783 (49.1) 1261 (45.5) 1650 (55.8)  
Outpatient facility 1851 (50.9) 1513 (54.5) 1305 (44.2)  
Type of AF, n (%) 9360     < .001
First detected 547 (15.1) 532 (19.2) 373 (12.6)  
Paroxysmal 936 (25.8) 865 (31.2) 692 (23.4)  
Persistent 693 (19.1) 641 (23.1) 496 (16.8)  
Long-standing persistent 143 (3.9) 114 (4.1) 134 (4.5)  
Permanent 1256 (34.6) 577 (20.8) 1210 (41.0)  
Unknown 58 (1.6) 44 (1.6) 49 (1.7)  
CHA2DS2-VASc score, median [IQR] 9358 3 [2–4] 2 [1–3] 4 [3–5] < .001
CHA2DS2-VASc quartiles, n (%)     < .001
Q1 (0–2) 1253 (34.5) 1834 (66.2) 520 (17.6)  
Q2 (3) 887 (24.4) 483 (17.4) 598 (20.3)  
Q3 (4) 777 (21.4) 312 (11.3) 734 (24.9)  
Q4 (≥ 5) 716 (19.7) 143 (5.2) 1101 (37.3)  
High TE risk, n (%) 9358 2865 (78.9) 1351 (48.7) 2771 (93.8) < .001
HAS-BLED score, median [IQR] 2 [1–2] 1 [0–2] 2 [1–3] < .001
High bleeding risk, n (%) 616 (17.0) 172 (6.2) 809 (27.4) < .001
EHRA score, median [IQR] 9362 2 [1–2] 2 [1–2] 2 [1–2] .002
EHRA II-IV, n (%) 9362 1892 (52.1) 1613 (58.2) 1536 (52.0) < .001
Previous stroke, n (%) 358 (9.9) 40 (1.4) 157 (5.3) < .001
Previous thromboembolic events, n (%) 529 (14.6) 193 (7.0) 325 (11.0) < .001
Hypertension, n (%) 2230 (61.4) 1253 (45.2) 2266 (76.7) < .001
Heart failure, n (%) 1327 (36.5) 419 (15.1) 1658 (56.1) < .001
Diabetes mellitus, n (%) 297 (8.2) 177 (6.4) 1613 (54.6) < .001
Lipid disorder, n (%) 1356 (38.4) 874 (32.5) 1512 (52.5) < .001
Congenital heart disease, n (%) 50 (1.4) 24 (0.9) 29 (1.0) .24
Valvular disease, n (%) 2200 (60.5) 615 (22.2) 1724 (58.3) < .001
CAD, n (%) 1093 (30.1) 273 (9.8) 1311 (44.4) < .001
CIED implant, n (%) 364 (10.2) 166 (6.1) 400 (13.7) < 0.001
Chronic kidney disease, n (%) 138 (3.8) 58 (2.1) 911 (30.8) < .001
History of bleeding, n (%) 311 (8.6) 23 (0.8) 156 (5.3) < .001
COPD, n (%) 446 (12.3) 80 (2.9) 267 (9.0) < .001
Anaemia, n (%) 176 (4.8) 14 (0.5) 268 (9.1) < .001
Predisposition to bleeding, n (%) 76 (2.1) 18 (0.6) 81 (2.7) < .001
Peripheral arterial disease, n (%) 297 (8.2) 131 (4.7) 318 (10.8) < .001
Liver disease, n (%) 125 (3.4) 17 (0.6) 79 (2.7) < .001
OSAS, n (%) 83 (2.3) 230 (8.3) 127 (4.3) < .001
Neoplasm, n (%) 513 (14.1) 40 (1.4) 162 (5.5) < .001
Hyperthyroidism, n (%) 305 (8.4) 47 (1.7) 84 (2.8) < .001
Hypothyroidism, n (%) 509 (14.0) 49 (1.8) 334 (11.3) < .001
Multi-morbidity, n (%) 3151 (86.9) 1312 (47.3) 2877 (97.6) < .001
Comorbidities, N Median [IQR] 3 [2–4] 1 [0–2] 4 [3–6]  
Comorbidities quartiles, n (%)     < .001
Q1 (0–2) 1289 (35.5) 2134 (76.9) 337 (11.4)  
Q2 (3) 901 (24.8) 313 (11.3) 518 (17.6)  
Q3 (4–5) 1024 (28.2) 272 (9.8) 1174 (39.8)  
Q4 (≥ 6) 414 (11.4) 55 (2.0) 918 (31.2)  
Frailty, n (%) 571 (16.5) 185 (7.0) 1003 (35.5) < .001
Polypharmacy, n (%) 9301 1801 (49.9) 941 (34.1) 2162 (73.7) < .001
Drugs, N Median [IQR] 4 [3–6] 4 [2–5] 6 [4–7]  
Drug quartiles, n (%)     < .001
Q1 (0–3) 1053 (29.2) 1272 (46.2) 345 (11.8)  
Q2 (4–5) 1457 (40.3) 1018 (36.9) 1034 (35.2)  
Q3 (6) 564 (15.6) 264 (9.6) 589 (20.1)  
Q4 (≥ 7) 537 (14.9) 202 (7.3) 966 (32.9)  
  1. Legend: AF atrial fibrillation, CAD coronary artery disease, CIED cardiac implantable electronic device, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CV cardiovascular, IQR interquartile range, OSAS obstructive sleep apnoea syndrome, PAD peripheral artery disease, RFs risk factors, TE thromboembolic